Advertisement

Journal of Endocrinological Investigation

, Volume 42, Issue 10, pp 1245–1252 | Cite as

Novel SLCO2A1compound heterozygous mutation causing primary hypertrophic osteoarthropathy with Bartter-like hypokalemia in a Chinese family

  • Y. Jiang
  • J. Du
  • Y.-W. Song
  • W.-B. Wang
  • Q.-Q. Pang
  • M. Li
  • O. Wang
  • X.-L. Lian
  • X.-P. Xing
  • W.-B. XiaEmail author
Original Article

Abstract

Purpose

Primary hypertrophic osteoarthropathy (PHO) is an inherited disease characterized by digital clubbing, periostosis and pachydermia with defects in the degradation of prostaglandin E2 (PGE2). Mutations in SLCO2A1 gene-encoding prostaglandin transporter (PGT) resulted in PHO, autosomal recessive 2 (PHOAR2). The spectrum of mutations and variable clinical complications of PHOAR2 has been delineated. In this study, we investigated a Chinese PHO family with a manifestation of Bartter-like hypokalemia.

Methods

Clinical manifestations were collected and genetic analyses were performed in the PHO family.

Results

The 33-year-old male proband had severe hypokalemia due to potassium loss from the kidney, while his brother had mild hypokalemia. After being treated with etoricoxib, the serum potassium level of the patient increased rapidly to the normal range which corresponded with the reduction in his serum PGE2 and PE2 metabolite (PGEM) levels. A novel SLCO2A1 compound heterozygous mutation of p.I284V and p.C459R was identified in two PHO patients in this family.

Conclusions

The present findings supported that the Bartter-like hypokalemia is a new complication of PHOAR2 caused by the high level of PGE2. Etoricoxib was demonstrated to be effective for the renal hypokalemia in PHO patients.

Keywords

Primary hypertrophic osteoarthropathy Prostaglandin E2 Hypokalemia SLCO2A1 Gene mutation 

Notes

Acknowledgements

The authors thank the patients for their involvements in this study. This study was supported by the National Natural Science Foundation of China (No. 81670714), the Beijing Natural Science Foundation (No. 7121012), the Scientific Research Foundation of Beijing Medical Development (No. 2007-3029), National Key Program of Clinical Science (WBYZ2011-873), and the CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-3-003), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Nos. 2017PT32020, 2018PT32001), Clinical Research Fund for Endocrine Disease Research Project of Chinese Medical Association (No. 13050790464) and Youth Fund of Peking Union Medical College Hospital (No. 2013019).

Compliance with ethical standards

Conflict of interest

All authors state that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of Ethics Committee of PUMCH and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Castori M, Sinibaldi L, Mingarelli R, Lachman RS, Rimoin DL, Dallapiccola B (2005) Pachydermoperiostosis: an update. Clin Genet 68:477–486CrossRefPubMedGoogle Scholar
  2. 2.
    Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, Helliwell PS, Latos-Bieleńska A, Phillips SE, Markham AF, Bennett CP, Bonthron DT (2008) Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 40:789–793CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang Z, Xia W, He J, Zhang Z, Ke Y, Yue H, Wang C, Zhang H, Gu J, Hu W, Fu W, Hu Y, Li M, Liu Y (2012) Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 90:125–132CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nomura T, Lu R, Pucci ML, Schuster VL (2004) The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin15 dehydrogenase. Mol Pharmacol 65:973–978CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang Z, He JW, Fu WZ, Zhang CQ, Zhang ZL (2013) Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab 98:E923–E933CrossRefPubMedGoogle Scholar
  6. 6.
    Tuysuz B, Yilmaz S, Kasapcopur O, Erener-Ercan T, Ceyhun E, Bilguvar K, Gunel M (2014) Primary hypertrophic osteoarthropathy caused by homozygous deletion in HPGD gene in a family: changing clinical and radiological findings with long-term follow-up. Rheumatol Int 34:1539–1544CrossRefPubMedGoogle Scholar
  7. 7.
    Bergmann C, Wobser M, Morbach H, Falkenbach A, Wittenhagen D, Lassay L, Ott H, Zerres K, Girschick HJ, Hamm H (2011) Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol 20:531–533CrossRefPubMedGoogle Scholar
  8. 8.
    Hou Y, Lin Y, Qi X, Yuan L, Liao R, Pang Q, Cui L, Jiang Y, Wang O, Li M, Dong J, Xia W (2018) Identification of mutations in the prostagl and in transporter gene SLCO2A1 and phenotypic comparison between two subtypes of primary hypertrophic osteoarthropathy (PHO): a single-center study. Bone 106:96–102CrossRefPubMedGoogle Scholar
  9. 9.
    Kaneko K, Uemura J, Okada K, Kumakura S, Ishikawa S, Saito T, Kuzuya T, Shimizu H, Sakamoto Y (1988) A case of pachydermoperiostosis with Bartter's syndrome. Nihon Naika Gakkai Zasshi 77:63–68CrossRefPubMedGoogle Scholar
  10. 10.
    Seyberth HW, Schlingmann KP (2011) Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 26:1789–1802CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yuan L, Chen L, Liao RX, Lin YY, Jiang Y, Wang O, Li M, Xing XP, Pang QQ, Jiajue R, Xia WB (2015) A common mutation and a novel mutation in the HPGD gene in nine patients with primary hypertrophic osteoarthropathy. Calcif Tissue Int 97:336–342CrossRefPubMedGoogle Scholar
  12. 12.
    Wang F, Zhang Y, Mao J, Yu Z, Yi Z, Yu L, Sun J, Wei X, Ding F, Zhang H, Xiao H, Yao Y, Tan W, Lovric S, Ding J, Hildebrandt F (2017) Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 32:1181–1192CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Asan XuY, Jiang H, Tyler-Smith C, Xue Y, Jiang T, Wang J, Wu M, Liu X, Tian G, Wang J, Wang J, Yang H, Zhang X (2011) Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol 12:R95CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sasaki T, Niizeki H, Shimizu A, Shiohama A, Hirakiyama A, Okuyama T, Seki A, Kabashima K, Otsuka A, Ishiko A, Tanese K, Miyakawa S, Sakabe J, Kuwahara M, Amagai M, Okano H, Suematsu M, Kudoh J (2012) Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci 68:36–44CrossRefPubMedGoogle Scholar
  15. 15.
    Nomura T, Lu R, Pucci ML, Schuster VL (2004) The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 65:973–978CrossRefPubMedGoogle Scholar
  16. 16.
    Nakanishi T, Tamai I (2017) Roles of organic anion transporting polypeptide 2A1(OATP2A1/SLCO2A1) in regulating the pathophysiological actions of prostaglandins. AAPS J 20:13CrossRefPubMedGoogle Scholar
  17. 17.
    Li SS, He JW, Fu WZ, Liu YJ, Hu YQ, Zhang ZL (2017) Clinical, biochemical, and genetic features of 41 Han Chinese families with primary hypertrophic osteoarthropathy, and their therapeutic response to etoricoxib: results from a six-month prospective clinical intervention. J Bone Miner Res 32:1659–1666CrossRefPubMedGoogle Scholar
  18. 18.
    Diggle CP, Parry DA, Logan CV, Laissue P, Rivera C, Restrepo CM et al (2012) Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat 33:1175–1181CrossRefPubMedGoogle Scholar
  19. 19.
    Guda K, Fink SP, Milne GL, Molyneaux N, Ravi L, Lewis SM et al (2014) Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev Res (Phila) 7:805–812CrossRefGoogle Scholar
  20. 20.
    Cheng R, Li M, Guo Y, Yao Y, Gao C, Yao Z (2013) Three novel mutations in the SLCO2A1 gene in two Chinese families with primary hypertrophic osteoarthropathy. Eur J Dermatol 23:636–639PubMedGoogle Scholar
  21. 21.
    Umeno J, Hisamatsu T, Esaki M, Hirano A, Kubokura N, Asano K et al (2015) A hereditary enteropathy caused by mutations in theSLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet 11:e1005581CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Squires RD, Huth EJ (1959) Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Investig 38:1134–1148CrossRefPubMedGoogle Scholar
  23. 23.
    Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL (2002) Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 282:F1103–F1110CrossRefPubMedGoogle Scholar
  24. 24.
    Pucci ML, Endo S, Nomura T, Lu R, Khine C, Chan BS et al (2006) Coordinate control of prostaglandin E2 synthesis and up take by hyperosmolarity in renal medullary interstitial cells. Am J Physiol Renal Physiol 290:F641–F649CrossRefPubMedGoogle Scholar
  25. 25.
    Nomura T, Chang HY, Lu R, Hankin J, Murphy RC, Schuster VL (2005) Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell. J Biol Chem 280:28424–28429CrossRefPubMedGoogle Scholar
  26. 26.
    Olesen ET, Fenton RA (2013) Is there a role for PGE2 in urinary concentration? J Am Soc Nephrol 24:169–178CrossRefPubMedGoogle Scholar
  27. 27.
    Rajagopal M, Thomas SV, Kathpalia PP, Chen Y, Pao AC (2014) Prostaglandin E2 induces chloride secretion through crosstalk between cAMP and calcium signaling in mouse inner medullary collecting duct cells. Am J Physiol Cell Physiol 306:C263–C278CrossRefPubMedGoogle Scholar
  28. 28.
    Riendeau D, Percival MD, Brideau C et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296(2):558–566PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  1. 1.Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Peking Union Medical CollegeChinese Academy of Medical ScienceBeijingChina

Personalised recommendations